Cardiovascular disease

LIB Therapeutics and Partner Hasten Biopharmaceuticals Announce Lerodalcibep Clinical Trial Application Acceptance by the Center for Drug Evaluation at the National Medical Products Administration in China

Retrieved on: 
Tuesday, March 19, 2024
Research, FDA, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Other Science, Science, Cardiovascular disease, NMPA, PCSK9, CVD, MAA, Refrigeration, CMC, EMA, CDE, Clinical trial, Therapy, National Medical Products Administration, Pharmaceutical industry

LIB Therapeutics, Inc. (LIB), a privately-held, late-stage biopharmaceutical company advancing Lerodalcibep, a potential best in class PCSK9 inhibitor for the treatment and prevention of cardiovascular disease (CVD), today announced that its regional partner in China, Hasten Biopharmaceuticals Co, Ltd. (Hasten), has received notification of acceptance for the clinical trial application for Lerodalcibep by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China.

Key Points: 
  • LIB Therapeutics, Inc. (LIB), a privately-held, late-stage biopharmaceutical company advancing Lerodalcibep, a potential best in class PCSK9 inhibitor for the treatment and prevention of cardiovascular disease (CVD), today announced that its regional partner in China, Hasten Biopharmaceuticals Co, Ltd. (Hasten), has received notification of acceptance for the clinical trial application for Lerodalcibep by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China.
  • In September 2023, LIB announced that it had entered into an agreement granting Hasten the rights to develop and commercialize Lerodalcibep in Greater China (Chinese Mainland, Hong Kong, Macau and Taiwan) and will be responsible for clinical development and regulatory approval in these territories.
  • The acceptance of the Lerodalcibep clinical trial application by the NMPA was based on the integrated data dossier provided by LIB, including CMC, non-clinical and clinical studies completed in the U.S., Europe, and rest of world as well as the clinical development plan in China proposed by Hasten.
  • “We are preparing our own Lerodalcibep BLA submission to the FDA, to be followed by MAA submission to EMA.

Fast Company Names egnite, Inc. One of Its Most Innovative Companies in 2024

Retrieved on: 
Tuesday, March 19, 2024
Cardiology, Software, Practice Management, Health, Artificial Intelligence, Medical Devices, Health Technology, Technology, Disease, Intelligence, Risk, Artificial intelligence, Patient, Stroke, Mortality, Death, A.I, Heart failure, Cardiovascular disease, Trailblazer, Physician, Pharmaceutical industry

Fast Company, the world’s leading progressive business media brand, announced egnite, Inc. as one of the World’s Most Innovative Companies in their 2024 ranking.

Key Points: 
  • Fast Company, the world’s leading progressive business media brand, announced egnite, Inc. as one of the World’s Most Innovative Companies in their 2024 ranking.
  • egnite, a leading digital health company specializing in artificial intelligence solutions to advance cardiovascular care, stands at the forefront of innovation in the healthcare sector.
  • The 2024 list showcases businesses pioneering advancements within their industries, setting new standards for innovation and paving the way for future breakthroughs.
  • As the company continues to leverage its technology to help improve patient care, it remains dedicated to shaping the future of cardiovascular health.

Global Markets for Emerging Insulin Drug and Delivery Technologies, with Focus on Syringes and Vials - ResearchAndMarkets.com

Retrieved on: 
Monday, March 18, 2024
Diabetes, Pharmaceutical, Health, Medical Supplies, Diagnosis, Cardiovascular disease, Prevalence, Disease, Insulin, ESG, Peripheral neuropathy, Syringe, Paratriathlon, Vial, Delivery, Pharmaceutical industry

The "Global Markets for Emerging Insulin Drug and Delivery Technologies: Focus on Syringes and Vials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Markets for Emerging Insulin Drug and Delivery Technologies: Focus on Syringes and Vials" report has been added to ResearchAndMarkets.com's offering.
  • This report discusses the implications of the growing diabetes epidemic on the global and regional markets for emerging insulin drug and delivery technologies.
  • Five-year global sales forecasts are provided for the major categories of insulin drug and delivery technologies and devices categories.
  • The market for insulin drug and delivery technologies will continue to grow significantly in many areas, notably regulatory compliance.

Cardio Diagnostics Holdings, Inc. to Showcase HeartRisk and Actionable Clinical Intelligence Version 3 at the American College of Cardiology’s 73rd Annual Scientific Session

Retrieved on: 
Thursday, March 14, 2024
Other Health, Software, General Health, Data Management, Medical Devices, Technology, Artificial Intelligence, Health Technology, Cardiology, Biotechnology, Other Technology, Health, Cardio, Genomics, Organization, Cardiovascular disease, ACI, Entrepreneurship, Patient, Artificial intelligence, Medicine, CHD, American College, Heart, Epigenomics, Moyamoya disease, ACC, Pharmaceutical industry

Cardio Diagnostics' mission is in lockstep with this year's ACC.24 conference theme, "Advancing Cardiovascular Care for All."

Key Points: 
  • Cardio Diagnostics' mission is in lockstep with this year's ACC.24 conference theme, "Advancing Cardiovascular Care for All."
  • All attendees including providers, provider organizations and potential industry partners will be able to learn more about Cardio Diagnostics' HeartRisk and Actionable Clinical Intelligence platforms at booth 3605.
  • Actionable Clinical Intelligence V.3: Building upon the success of its predecessor, which debuted at ACC in 2023, Actionable Clinical Intelligence V.3 takes precision medicine to new heights.
  • "Our new innovative solutions, HeartRisk and Actionable Clinical Intelligence V.3, can potentially revolutionize how healthcare professionals approach cardiovascular disease prevention, detection and management.

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Retrieved on: 
Wednesday, March 13, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, MD, Patient, Cardiovascular disease, Small RNA, RNA, Moyamoya disease, ASCVD, Mole, Therapy, Tutoring

Zerlasiran is a siRNA (short interfering RNA) designed to lower the body’s production of Lp(a), a key genetic risk factor for cardiovascular disease affecting up to 20% of the world’s population.

Key Points: 
  • Zerlasiran is a siRNA (short interfering RNA) designed to lower the body’s production of Lp(a), a key genetic risk factor for cardiovascular disease affecting up to 20% of the world’s population.
  • These data demonstrated a highly significant reduction from baseline in Lp(a) compared to placebo to 36 weeks (primary endpoint).
  • Median percentage reduction in Lp(a) of 90% or greater were observed for both doses at week 36.
  • “We are excited about the emerging phase 2 data, which are very consistent with phase 1 results and support a competitive profile for treating patients with high Lp(a),” said Steven Romano, MD, Head of Research and Development at Silence.

New HES Report: The Truth About 10,000 Steps a Day

Retrieved on: 
Tuesday, March 12, 2024
Mental Health, Research, Human Resources, Professional Services, Other Education, Health, General Health, Science, Education, Steps, Death, Cardiovascular disease, Job satisfaction, Confusion, HES, Social support, Risk, White paper, Cancer, Gold, Multimedia, Dementia, Management

View the full release here: https://www.businesswire.com/news/home/20240312637494/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240312637494/en/
    Thumbnail of white paper - The Truth About 10,000 Steps A Day (Photo: Business Wire)
    “10,000 steps a day has been a popular recommendation for decades, but some confusion and misinformation have surrounded its validity,” explains lead author and employee well-being consultant Bob Merberg.
  • It also highlights a link between more steps, up to about 10,000, and a lower risk of cancer as well as cardiovascular disease.
  • In addition, the paper discusses a study result that associates 10,000 steps each day with lower risk of dementia.
  • “The research is clear — taking 10,000 steps a day has significant health benefits,” Bob emphasizes.

Global Guidewires (Nitinol, Stainless Steel, Others) Market Report 2024: Analysis & Forecasts 2019-2022 and 2023-2029 - Minimally Invasive Techniques Expand, Boosting Guidewire Utilization - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2024
General Health, Health, Medical Supplies, Medical Devices, Disease, PVI, Friction, ERCP, Coronary artery disease, Conditional sentence, Bacteria, Epidemiology, Specialization, Risk, Investment, Infection, Patient safety, USD, Surgery, Non-communicable disease, Cardiovascular disease, Fungal infection, Obesity, Biotechnology, Peripheral artery disease, Porter's five forces analysis, Diabetes, Chlorhexidine, World Health Organization, Safety, Fatigue, Hypertension, Cardiology, Neurology, Urology, Prevalence, Death, PCI, Diagnosis, Arrhythmia, Temperature, Growth, Incidence, Anatomy, SWOT, Mortality, Stainless steel, WHO, Nickel titanium, Physician, Medical imaging

Guidewires Market is being propelled increasing prevalence of cardiovascular diseases, technological advancements in guidewire design and materials, rising demand for minimally invasive procedures, and expanding healthcare infrastructure in developing economies.

Key Points: 
  • Guidewires Market is being propelled increasing prevalence of cardiovascular diseases, technological advancements in guidewire design and materials, rising demand for minimally invasive procedures, and expanding healthcare infrastructure in developing economies.
  • As the prevalence of risk factors such as obesity, diabetes, and hypertension increase, so does the incidence of cardiovascular diseases.
  • Guidewires are essential tools in percutaneous coronary interventions (PCI), peripheral vascular interventions (PVI), and electrophysiology procedures, driving the demand for guidewires.
  • The increasing prevalence of chronic diseases worldwide drives the demand for guidewires by necessitating minimally invasive interventions for diagnosis and treatment.

Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR

Retrieved on: 
Monday, March 11, 2024
Health, Medical Devices, Surgery, Clinical Trials, Research, Science, Cardiology, Registry, CRT, Aortic stenosis, TVT, Patient, Journal, Stroke, Mortality, Ultra, Oakland University, MD, Cardiovascular disease, American College, TAVR, Arrest, JACC, PVL, Medical imaging

Edwards Lifesciences (NYSE: EW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform.

Key Points: 
  • Edwards Lifesciences (NYSE: EW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform.
  • In a second study presented during the late-breaking clinical trials session, small Edwards SAPIEN TAVR valves demonstrated equally excellent outcomes at 3 years as compared to larger SAPIEN TAVR valve sizes.
  • The study found that all Edwards TAVR platforms demonstrated excellent PVL results.
  • An analysis of 8,100 propensity matched patients across more than 800 sites in the United States found that patients treated with a 20mm Edwards SAPIEN valve demonstrated excellent all-cause mortality and stroke outcomes at 3-years, equivalent to those receiving 23, 26 and 29mm SAPIEN valve sizes.

RSNA: Early Coronary Disease, Impaired Heart Function Found in Asymptomatic People with HIV

Retrieved on: 
Thursday, April 4, 2024
Biomedicine, Cardiovascular disease, MRI, Coronary artery disease, HIV, Didanosine, Viral load, Education, Patient, Facial muscles, Research, Kidney, University, Death, Physical examination, NIH, Society, Life expectancy, Risk, Moyamoya disease, OAK, World Health Organization, RSNA, DRS, Heart, Radiation, Bangladesh Technical Education Board, Digestive, Synthetic control method, Health, Person, Pharmaceutical industry

OAK BROOK, Ill., April 4, 2024 /PRNewswire-PRWeb/ -- A new study found increased coronary vessel wall thickness that was significantly associated with impaired diastolic function in asymptomatic, middle-aged individuals living with HIV. The study was published today in Radiology: Cardiothoracic Imaging, a journal of the Radiological Society of North America (RSNA).

Key Points: 
  • A new study found increased coronary vessel wall thickness that was significantly associated with impaired diastolic function in asymptomatic, middle-aged individuals living with HIV.
  • The ability to detect early coronary artery disease in persons living with HIV and potentially prevent detrimental effects on the heart muscle is important.
  • This research shows the impact of HIV on developing subtle subclinical coronary artery disease and its effects on heart function.
  • "This research shows the impact of HIV on developing subtle subclinical coronary artery disease and its effects on heart function."

Johnson & Johnson to Showcase its Broad Scientific Leadership and Latest Innovations to Combat Cardiovascular Disease at ACC.24

Retrieved on: 
Thursday, April 4, 2024
Cardiology, Abstract, Rivaroxaban, Cardiovascular disease, Worldwide, Peripheral artery disease, Health, Atrial fibrillation, Risk, Patient, Knowledge, PAD, Stroke, Research, Death, Statistics, American College, Danger, Johnson & Johnson, Acute coronary syndrome, Pharmaceutical industry

NEW BRUNSWICK, N.J., April 4, 2024 /PRNewswire/ -- Johnson & Johnson announced today that clinical and real-world evidence from its cardiovascular portfolio will be featured at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) taking place April 6-8, 2024, in Atlanta, Georgia. Eleven abstracts, including five oral presentations, will showcase data from Company-sponsored studies demonstrating therapeutic benefit of breakthrough medicines, such as XARELTO® (rivaroxaban), and interventional technologies, such as those from Abiomed® and Biosense Webster®, to help treat cardiovascular diseases, including atrial fibrillation (AF) and peripheral artery disease (PAD).

Key Points: 
  • "At ACC.24, we look forward to sharing the latest research and innovation from our broad portfolio, including XARELTO®, to equip clinicians and researchers with knowledge and insights that can help transform cardiovascular care for all."
  • Johnson & Johnson is committed to elevating the standard of care in cardiovascular diseases and unlocking the potential of medicines and solutions of tomorrow.
  • Several data presentations at ACC.24 demonstrate how the Company is improving outcomes for people living with cardiovascular disease, including older adults and other patient populations often considered hard to treat.
  • The data we're presenting at ACC.24 demonstrate how we're continuing to deliver on our commitment," said Tim Schmid, Executive Vice President and Worldwide Chairman, Johnson & Johnson MedTech.